Reactivación de Strongyloides stercoralis en pacientes con neumonía por SARS-CoV-2 en tratamiento con dexametasona

Feria, Lucía; Torrado, Missia; Antón-Vázquez, Vanesa

doi:10.1016/j.medcli.2021.05.004

Cited by 8 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers Feria et al (2022) reported two cases of reactivation of Strongyloides stercoralis in patients with COVID-19. A 44-year-old man from Bolivia who has lived in Spain for 17 years has been hospitalized with severe pneumonia from SARS-CoV-2.…”

Section: Resultsmentioning

confidence: 99%

Steroid therapy in COVID-19 as a triggering factor for Strongyloides stercoralis hyperinfection

Norberg,

Manhães

et al. 2023

View full text Add to dashboard Cite

Strongyloides stercoralis is a nematode with worldwide geographical distribution, most frequent in tropical areas, especially prevalent in areas with poor sanitary conditions. The disease caused by S. stercoralis is known as strongyloidiasis and parasitism is usually asymptomatic. Infection by this nematode may, however, present severe symptoms in hosts with immune system deficiencies. The aim of this research is to investigate, through a review of current scientific literature, the treatment of severe COVID-19 with immunosuppressants as a triggering factor for Strongyloides stercoralis hyperinfection. There are scarce records in the scientific literature on Strongyloides stercoralis hyperinfection consequent to treatment of COVID-19 with steroid drugs, mainly in endemic areas. We believe that this complication may be highly underestimated. The finding of eosinophilia in the blood count of patients after receiving immunosuppressive therapy during COVID-19 corticoid treatment is an important marker for the possibility of Strongyloides stercoralis hyperinfection and should prompt laboratory studies for nematode screening, mainly serology and PCR.

show abstract

Section: Resultsmentioning

confidence: 99%

Steroid therapy in COVID-19 as a triggering factor for Strongyloides stercoralis hyperinfection

Norberg,

Manhães

et al. 2023

View full text Add to dashboard Cite

show abstract

Strongyloides Hyperinfection Syndrome Following Immunosuppressant Therapy for COVID‐19: A Case Report With Literature Review

Sharma,

Islam,

Alam

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Strongyloides hyperinfection and disseminated infections are usually associated with immunosuppression; these severe manifestations occur in a minority of cases. The use of immunosuppressants such as corticosteroids and Baricitinib for treating COVID‐19 pneumonia can be responsible for patients' immunosuppression and cause Strongyloides hyperinfection syndrome. The chance increases when the patient belongs to countries or regions where chronic infection with Strongyloides is more prevalent. This case report describes the clinical scenario of a 78‐year‐old man from southeastern Bangladesh who was initially diagnosed with COVID‐19 pneumonia. His condition improved after receiving corticosteroid therapy for approximately 1 month at various doses and Baricitinib therapy for more than a week due to moderate‐to‐severe COVID‐19 pneumonia. Approximately 2 months later, he presented with low‐grade fever, diarrhea, and itching throughout the body. Blood analysis revealed eosinophilia; stool examination revealed Rhabditiform larvae of Strongyloides stercoralis. The patient was diagnosed with Strongyloides hyperinfection syndrome and treated with Albendazole and Ivermectin. His clinical condition gradually improved, and he was discharged from the hospital. The stool sample was sent for a repeat microscopic examination after 14 days, which yielded a negative result. Clinicians should be more vigilant while prescribing corticosteroids and other immunosuppressants for a prolonged period. Proper screening to identify asymptomatic cases of strongyloidiasis, followed by empirical treatment of screening‐positive cases, prompt detection, and management of severe manifestations, is crucial to reduce further morbidity and mortality related to Strongyloides stercoralis.

show abstract

Dexamethasone

2021

Reactions Weekly

View full text Add to dashboard Cite

Reactivación de Strongyloides stercoralis en pacientes con neumonía por SARS-CoV-2 en tratamiento con dexametasona

Cited by 8 publications

References 4 publications

Steroid therapy in COVID-19 as a triggering factor for Strongyloides stercoralis hyperinfection

Steroid therapy in COVID-19 as a triggering factor for Strongyloides stercoralis hyperinfection

Strongyloides Hyperinfection Syndrome Following Immunosuppressant Therapy for COVID‐19: A Case Report With Literature Review

Dexamethasone

Contact Info

Product

Resources

About